Key result
This paper is a study protocol for the TELEMED-HF randomized controlled trial and does not report clinical results.
Why the study?
Does an electronic medication adherence support system improve medication adherence, reduce hospitalizations, and decrease healthcare consumption in patients with chronic systolic heart failure?
RCT (n=400)
Open-label
1:1 blocked randomization
No
Does an electronic medication adherence support system improve medication adherence, reduce hospitalizations, and decrease healthcare consumption in patients with chronic systolic heart failure?
The TELEMED-HF study protocol outlines a randomized controlled trial to evaluate whether a telemonitoring medication adherence support system improves adherence and clinical outcomes in patients with chronic heart failure.
Protocol for TELEMED-HF RCT tests telemonitoring adherence support in systolic HF; leaves open clinical benefits until results emerge.
BACKGROUND: Frequent rehospitalisations and poorer survival chances in heart failure (HF) patients may partly be explained by poor medication adherence. There are multiple medication-related reasons for suboptimal adherence, but psychological reasons may also be important. A novel TELEmonitoring device may improve MEDication adherence in HF patients (TELEMED-HF). TELEMED-HF is a randomized, controlled clinical intervention trial designed to examine (1) the efficacy and cost-efficiency of an electronic medication adherence support system in improving and monitoring HF patients' medication adherence; (2) the effect of medication adherence on hospitalizations and health care consumption; as well as on (3) clinical characteristics, and Quality of Life (QoL); and (4) clinical, sociodemographic, and psychological determinants of medication adherence. METHODS/DESIGN: Consecutive patients with chronic, systolic HF presenting to the outpatient clinic of the TweeSteden Hospital, The Netherlands, will be approached for study participation and randomly assigned (1:1) following blocked randomization procedures to the intervention (n = 200) or usual care arm (n = 200). Patients in the intervention arm use the medication support device for six months in addition to usual care. Post-intervention, patients return to usual care only and all patients participate in four follow-up occasions over 12 months. Primary endpoints comprise objective and subjective medication adherence, healthcare consumption, number of hospitalizations, and cost-effectiveness. Secondary endpoints include disease severity, physical functioning, and QoL. DISCUSSION: The TELEMED-HF study will provide us a comprehensive understanding of medication adherence in HF patients, and will show whether telemonitoring is effective and cost-efficient in improving adherence and preventing hospitalization in HF patients. TRIAL REGISTRATION NUMBER: NCT01347528.
No takes yet. Share an insight, caveat, or question.
Kessing et al. (2011) conducted an RCT in Chronic systolic heart failure (n=400). Medication Adherence Support System (MASS) vs. Usual care was evaluated on Objective and subjective medication adherence, healthcare consumption, number of hospitalizations, and cost-effectiveness. This paper is a study protocol for the TELEMED-HF randomized controlled trial and does not report clinical results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: